Tells me RNAi doesn't get into cns by itself. So we are moving to extreme measures. Thus confirming fears about systemic RNAi admin.
Further, this is just a feasibility agreement ('sure, give it a shot') and mdt has allowed experimentation with other its cns devices, all of which have failed basically, for years.
Pumps, co-localization, suction, pressure differentials. Ugh, nothing succeeds. Growth factors, stem cell mobilizers, dopamine producing cells, neuro-protectants, neuro-tropics--and here comes antisense.
And, if I understand the RNAi theory right, you would probably need continuous RNA silencing, yes? I could see a different, more durable, treatment paradigm, such as gene therapy, being administered via device + hole in the head, but RNAi?
These, right or wrong, were the reasons for my surprise at stock activity. |
